EN DE
STOCK COMPARISON

Amgen vs Eli Lilly and: Fair Value & Quality

Both stocks run through our valuation models. Here is how Amgen (AMGN) and Eli Lilly and (LLY) compare, as of Aug 8, 2026.

As of Aug 8, 2026, Fair Value Calculator sees Amgen as the less overvalued of the two: Amgen trades at $405 versus a fair value of $252 (-38%), while Eli Lilly and trades at $1,192 versus $397 (-67%).
Amgen
AMGN · USD · Health Care
-38%
upside to fair value
overvalued
Price$405
Fair Value$252
Quality71/100
Eli Lilly and
LLY · USD · Health Care
-67%
upside to fair value
overvalued
Price$1,192
Fair Value$397
Quality75/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

AmgenEli Lilly and
Valuation
25.3×P/E (TTM)42.2×
5.27×P/S (TTM)14.67×
22.65×P/B39.94×
14.0×EV/EBITDA30.2×
2.02×PEG1.54×
2.7%Dividend yield0.5%
$9.66Dividend per share$6.23
Profitability
21%Net margin35%
34%Operating margin49%
101%Return on equity107%
8%Return on assets21%
Growth
6%Revenue growth (YoY)56%
11.8%Avg. growth/yr (3Y)31.7%
7.6%Avg. growth/yr (5Y)21.6%
Balance & size
5.78×Debt / equity1.54×
$196BMarket cap$1.1T
healthyGrowth qualitymixed

Eli Lilly and leads: 5 to 9 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Amgenof which business quality 60 · market factors 80 Eli Lilly andof which business quality 65 · market factors 81
ProfitabilityMargins and returns on capital today
64
85
Quality GrowthAre margins and returns improving?
79
86
CashflowEarnings quality: real cash, not paper profit
78
51
Fin. StrengthBalance sheet, leverage, solvency risk
20
53
InvestmentDisciplined investing over empire-building
42
15
Low VolatilityCalm price path (market factor)
86
73
MomentumPrice trend over the last 3–12 months (market factor)
70
78
52W MomentumDistance to the 52-week high (market factor)
89
94
Net IssuanceBuybacks instead of dilution
81
93

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Amgen

DCF Models$257
Earnings-Based$151
Dividend Discount$167
Multiples$225
Asset-Based$10.75
Growth DCF$198
Economic Profit$129
Growth Earnings$247

25 of 26 models see the stock below the current price.

Eli Lilly and

DCF Models$323
Earnings-Based$239
Dividend Discount$115
Multiples$303
Asset-Based$19.94
Growth DCF$171
Economic Profit$347
Growth Earnings$353

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Amgen
Bear $139Fair Value $252Bull $340
$405 = current price (white tick)
Eli Lilly and
Bear $222Fair Value $397Bull $582
$1,192 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Amgen · Health Care

Quality score71 · Top 25%
Fair value upside-38% · below median

Eli Lilly and · Health Care

Quality score75 · Top 25%
Fair value upside-67% · bottom 25%

Bottom line

As of Aug 8, 2026, Fair Value Calculator sees Amgen as the less overvalued of the two: Amgen trades at $405 versus a fair value of $252 (-38%), while Eli Lilly and trades at $1,192 versus $397 (-67%).

Eli Lilly and has the higher quality score (75/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.